Pfizer Delivers On Biosimilars Strategy
Reports Biosimilars Sales Up By 19% To $911m In 2019
Executive Summary
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.